Compare RERE & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RERE | IRWD |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 859.3M | 741.8M |
| IPO Year | 2021 | 2009 |
| Metric | RERE | IRWD |
|---|---|---|
| Price | $4.87 | $3.05 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.94 |
| AVG Volume (30 Days) | 1.3M | ★ 3.1M |
| Earning Date | 03-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $26.81 | $57.95 |
| Revenue Next Year | $22.92 | $4.39 |
| P/E Ratio | $34.57 | ★ $21.57 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $2.00 | $0.55 |
| 52 Week High | $6.47 | $5.78 |
| Indicator | RERE | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 36.92 | 32.58 |
| Support Level | $3.87 | $1.38 |
| Resistance Level | $4.89 | $3.92 |
| Average True Range (ATR) | 0.29 | 0.24 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 4.05 | 3.37 |
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.